IP Library Granted Patent US 10,429,390
Granted Patent B2
US 10,429,390 · App. 14/652,407 · Granted Oct 1, 2019

Antibody cocktail systems and methods for classification of histologic subtypes in lung cancer

Inventor: David Tacha (Vacaville, CA)
Assignee: Biocare Medical, LLC
G01N33/57423G01N2800/52
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,429,390
App. No.
14/652,407
Granted
Oct 1, 2019
Kind
B2
Abstract

The present invention relates to compositions and detection systems of antibodies or fragments thereof, wherein at least two antibodies or fragments thereof binds specifically to squamous cell carcinoma (SCC) and/or adenocarcinoma (ADC). Methods for using the antibodies in diagnosis, prognosis, and assessing efficacy of treatment is further included as well as kits including such compositions and detection systems.

Claims (10)

1. A lung cancer detection system comprising:

a cocktail of two primary antibodies,

wherein a first primary antibody of said cocktail comprises an anti-p40 mouse monoclonal antibody, clone BC28, which specifically binds to squamous cell carcinoma (SCC); and

wherein a second primary antibody of said cocktail comprises an anti-TTF-1 mouse monoclonal antibody which specifically binds to adenocarcinoma (ADC).

2. A lung cancer detection system according to claim 1 and further comprising at least one antibody-enzyme conjugate.

3. A lung cancer detection system according to claim 2 and further comprising at least one chromogen.

4. A lung cancer detection system according to claim 2 wherein said at least one antibody-enzyme conjugate comprises an antibody selected from a group consisting of anti-rabbit antibody, anti-mouse antibody, anti-chicken antibody, anti-horse antibody, anti-rat antibody, anti-goat antibody, anti-sheep antibody, and any combination thereof.

5. A lung cancer detection system according to claim 4 wherein said at least one antibody-enzyme conjugate comprises an enzyme selected from a group consisting of horseradish peroxidase (HRP), alkaline phosphate (AP), glucose oxidase, β-galactosidase, and any combination thereof.

6. A lung cancer detection system according to claim 3 wherein said at least one chromogen is selected from a group consisting of 3,3′-diaminobenzidine (DAB); Fast Red; 3-amino-9-ethylcarbazole (AEC); Fast Blue; 3,3′,5,5′-tetramethylbenzidine (TMB); 5-Bromo-4-chloro-3-indolyl phosphate (BCIP); nitro blue tetrazolium (NBT); tetranitrobluetetrazolium (TNBT); New fuschin, 5-bromo-4-chloro-3-indolyl-β-D-galactopyranoside (X-Gal); 5-Bromo-3-indolyl β-D-galactopyranoside (Bluo-Gal); and any combination thereof.

7. A lung cancer detection system according to claim 2 wherein an antibody of said at least one antibody-enzyme conjugate binds to at least one of said two primary antibodies.

Assignments (5)
RELEASE OF SECURITY INTEREST Recorded Jun 25, 2026
From: VARAGON CAPITAL PARTNERS AGENT, LLC, AS ADMINISTRATIVE AGENT
To: BIOCARE MEDICAL LLC
Reel/Frame 075082/0723 →
SECURITY INTEREST Recorded Dec 9, 2021
From: BIOCARE MEDICAL LLC
To: VARAGON CAPITAL PARTNERS AGENT, LLC, AS ADMINISTRATIVE AGENT
Reel/Frame 058344/0799 →
RELEASE OF SECURITY INTEREST Recorded Dec 9, 2021
From: VARAGON CAPITAL PARTNERS AGENT, LLC, AS ADMINISTRATIVE AGENT
To: BIOCARE MEDICAL LLC
Reel/Frame 058351/0058 →
SECURITY INTEREST Recorded Aug 25, 2017
From: BIOCARE MEDICAL LLC
To: VARAGON CAPITAL PARTNERS AGENT, LLC, AS ADMINISTRATIVE AGENT
Reel/Frame 043401/0661 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 5, 2015
From: TACHA, DAVID
To: BIOCARE MEDICAL LLC
Reel/Frame 036255/0319 →
Continuity (2)
Provisional Application 61738938 · Dec 18, 2012
Related Publication 20150309035A1 · Oct 29, 2015